In the mid-1970s, the prestigious Rhodes Scholarship, the program that gives US recipients the chance to study at Oxford for two to three years, included just one or two future scientists per year, out of 32 awardees.
These papers were selected from multiple disciplines from the Faculty of 1000, a Web-based literature-awareness tool http://www.facultyof1000.com.R. Ando et al., "Regulated fast nucleocytoplasmic shuttling observed by reversible protein highlighting," Science, 306:1370-3, Nov. 19, 2004.The authors describe a new fluorophore (Dronpa) that has a high quantum yield as well as being remarkably photochromic. Dronpa can be interconverted between bright (fluorescent) and dark (nonfluorescent) states by
To any movie buff, TM7 refers to the 1960 John Sturges movie, The Magnificent Seven, in which a 30-year-old Steve McQueen burst onto the scene fighting alongside Yul Brynner, Charles Bronson, Robert Vaughn, and James Coburn to defend the homes of an oppressed Mexican peasant village.
has built an entire company around its Dynabeads, which are tiny paramagnetic particles that bind target cells, proteins, or nucleic acids, and can be removed in seconds with a magnet once their work is done.
In a recent three-hour session at a Chicago hotel room, the University of Wisconsin's technology transfer office hammered out the final details of licensing deal that granted Durham, NC-based Inspire Pharmaceuticals the right to use several patents to develop glau coma treatments.
Joelle BoltAfter garnering data on the harmful effects of dust from sewage sludge used as fertilizer on US and Canadian farms, David Lewis, former microbiologist with the Environmental Protection Agency (EPA), spoke out in Nature articles.12 The ensuing confrontation with his superiors would get him terminated from the EPA. "I never thought of myself as a whistleblower," he says. To Lewis, whistleblowers pointed fingers at people who fraudulently spent government money to buy things like private
Germany's belated attempt to bring its biotechnology patent law into compliance with an EU directive issued in 1998 appears to contradict what the European Union mandated, meaning the issue could end up being debated in the European Court of Justice.